Press Releases May 28, 2026 08:00 AM

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Akebia Therapeutics to Present at 2026 Jefferies Global Healthcare Conference

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
AKBA

Akebia Therapeutics announced that its Chief Financial and Business Officer and Chief Commercial Officer will present at the 2026 Jefferies Global Healthcare Conference. The company focuses on biopharmaceutical treatments for kidney disease and is headquartered in Cambridge, Massachusetts.

Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
AKBA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Akebia Therapeutics will present at a major healthcare investor conference, potentially increasing visibility among investors.
  • Presentation led by senior executives including CFO and Chief Commercial Officer, signaling possible updates on financial and commercial strategies.
  • The event offers a platform to highlight advancements and future plans related to kidney disease treatments.
  • Impacted sectors include biotech, pharmaceuticals, and healthcare investment markets.

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Erik Ostrowski, Chief Financial and Business Officer, and Nicholas Grund, Chief Commercial Officer, will present at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 7:35 AM ET in New York, NY.

A live webcast of the presentation can be accessed through the “Investors” section of Akebia’s website at https://ir.akebia.com. A replay of the webcast will also be available for 90 days following the presentation.

The 2026 Jefferies Global Healthcare Conference will take place June 2-4, 2026, in New York, NY.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release. 

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com 


Risks

  • No new product data or financial guidance provided, which may limit investor enthusiasm.
  • Uncertainty around the company's commercial prospects and pipeline developments until detailed updates are disclosed.
  • Broader biotech sector volatility could affect investor response regardless of the presentation’s content.

More from Press Releases

Cipher Digital Inc. Announces Proposed Offering of $810.0 Million of Senior Secured Notes Jun 8, 2026 Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal Jun 8, 2026 Global-e to Participate in Morgan Stanley US Financials Conference Jun 8, 2026 Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses Jun 8, 2026 Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives Jun 8, 2026